RiboX’s Circular RNA CAR-T IND Clearance Forces the Industry to Rethink Everything It Knows About Cell Therapy Trial Design
FDA cleared RiboX's RXIM002 IND for the first circular RNA-based in vivo CAR-T therapy — here's what it means...
Adaptive Clinical Trial Design Adaptive Trial Design Addiction Psychiatry AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trials CLINOPS WATCHDOG CNS Trials Conference Coverage CRO Consolidation Decentralized Clinical Trials Digital Health Technologies dual diagnosis eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy FDA Warning Letter GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
FDA cleared RiboX's RXIM002 IND for the first circular RNA-based in vivo CAR-T therapy — here's what it means...
FDA clears IND for circular RNA CAR-T therapy RXIM002, enabling subcutaneous dosing and accelerated Phase 1 trial design for...
AI drug discovery raised $8.9B in 2024, yet no AI-discovered drug holds FDA approval. The gap between algorithmic promise...
David Sinclair launches Lifespan media platform to improve public understanding of longevity science research and clinical trials.
FDA authorizes CLiK Extra for New World screwworm prevention in livestock, marking the third EUA-backed tool in the U.S....
A Phase 1 trial delivers B7-H3-targeting CAR-T cells directly into the brain of recurrent GBM patients — and the...
CytoSorbents pursues FDA De Novo classification for DrugSorb-ATR to address perioperative bleeding in cardiac surgery patients.
Theriva Biologics doses first patient in VIRAGE2 trial of VCN-01 for metastatic pancreatic cancer, testing increased dosing frequency with...
MetaVia's DA-1726 reaches highest doses in Phase 1 study with 9.1% mean body weight loss at eight weeks, ahead...
Vivani Medical completes dosing in Phase 1 trial of semaglutide implant designed to deliver the weight-loss drug continuously for...